Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-16 of 16

Sort by

Sort Order Select

Journal Articles

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Blood (2023) 142 (Supplement 1): 6907.

https://doi.org/10.1182/blood-2023-181999

Published: 2023

Journal Articles

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Giulio Cassanello, Efrat Luttwak, Sean M. Devlin, Alejandro Luna De Abia, Magdalena Corona, Ivan Landego, Allison Parascondola, Amethyst Saldia, Ana Alarcon Tomas, Parastoo B. Dahi, Richard J. Lin, M. Lia Palomba, Jae H. Park, Gilles Salles, Miguel-Angel Perales, Michael Scordo, Roni Shouval, Gunjan L. Shah

Blood (2023) 142 (Supplement 1): 6898.

https://doi.org/10.1182/blood-2023-190500

Published: 2023

Journal Articles

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

Blood (2023) 142 (Supplement 1): 7156.

https://doi.org/10.1182/blood-2023-190332

Published: 2023

Journal Articles

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Blood (2023) 142 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2023-181997

Published: 2023

Journal Articles

Higher CD4+ T Cell Counts after CAR-T in Large B-Cell Lymphomas Are Significantly Associated with Better Overall Survival

Danny Luan, Roni Shouval, Teng Fei, Efrat Luttwak, Alejandro Luna, Magdalena Corona, Maria Lia Palomba, Allison Parascondola, Michael Scordo, Gunjan L. Shah, Susan DeWolf, Miguel-Angel Perales

Blood (2023) 142 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2023-184909

Published: 2023

Journal Articles

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1639.

https://doi.org/10.1182/blood-2023-179641

Published: 2023

Journal Articles

Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood (2023) 142 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2023-187783

Published: 2023

Journal Articles

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Sireesha Asoori, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Larissa Brunaldi, Radhika Bansal, Andre De Menezes Silva Corraes, Kwee Yong, Catriona Mactier, Magdalena Corona, Adolfo Jesús Sáez Marín, Despina Fotiou, Meletios Athanasios Dimopoulos, Saurabh Chhabra, Sikander Ailawadhi, Ricardo Parrondo, Thomas Martin, Brian GM Durie, Yi Lin

Blood (2023) 142 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2023-190793

Published: 2023

Journal Articles

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4889.

https://doi.org/10.1182/blood-2023-187240

Published: 2023

Journal Articles

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2023-187338

Published: 2023

Journal Articles

Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Magdalena Corona De Lapuerta, Roni Shouval, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Connie Lee Batlevi, Joshua A Fein, Sergio A Giralt, Richard J. Lin, Karthik Nath, Maria Lia Palomba, Allison Parascondola, Gunjan L. Shah, Gilles Salles, Michael Scordo, Moneeza Walji, Miguel-Angel Perales, Parastoo B Dahi

Blood (2022) 140 (Supplement 1): 12770–12772.

https://doi.org/10.1182/blood-2022-163457

Published: 2022

Journal Articles

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 648–650.

https://doi.org/10.1182/blood-2022-162286

Published: 2022

Journal Articles

Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

Blood (2022) 140 (Supplement 1): 4671–4672.

https://doi.org/10.1182/blood-2022-157455

Published: 2022

Journal Articles

Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia

Alejandro ZURDO Castronuño, Miriam Solera Sainero, Magdalena Corona, Monserrat Torres, Guiomar Casado-Fernandez, Fernando Ramos-García, Javier Garcia-Pérez, María Aranzazú Murciano-Antón, María Jesús Blanchard, Juan Marquet Palomanes, Fernando Martin Moro, Mayte Pérez-Olmeida, Javier López Jiménez, Maria Teresa Coiras, Sara Rodriguez-Mora, Valentín Garcia-Gutiérrez

Blood (2022) 140 (Supplement 1): 3923–3924.

https://doi.org/10.1182/blood-2022-169512

Published: 2022

Journal Articles

Characterization of the Humoral and Cellular Immune Response Against the Natural Infection By Sars-Cov-2 in Oncohematological Patients with Post-COVID19 Autologous Transplantation

Adrián Sánchez-Tornero, Lorena Vigon, Guiomar Casado-Fernandez, Javier Garcia-Pérez, Elena Mateos, Magdalena Corona De Lapuerta, Sara Rodriguez-Mora, Monserrat Torres, María Aranzazú Murciano-Antón, Mayte Pérez-Olmeida, Javier Lopez Jimenez, Maria Rosa López-Huertas, Maria Teresa Coiras, Valentín Garcia-Gutiérrez

Blood (2021) 138 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2021-153223

Published: 2021

Journal Articles

Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19

Magdalena Corona De Lapuerta, Sara Rodriguez-Mora, Guiomar Casado-Fernandez, Javier Garcia-Pérez, Lorena Vigon, María Aranzazú Murciano-Antón, María Jesús Blanchard, Juan Marquet Palomanes, Fernando Martin Moro, Pablo Palomo Rumschisky, Mayte Pérez-Olmeida, Javier López Jiménez, Maria Rosa López-Huertas, Maria Teresa Coiras, Valentín Garcia Gutierrez

Blood (2021) 138 (Supplement 1): 195.

https://doi.org/10.1182/blood-2021-152943

Published: 2021

NARROW

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Detection of CAR-T Cell Persistence with Digital Droplet PCR: Correlation of In Vivo Expansion with Clinical Outcomes in a Cohort of B-Cell Lymphoma Patients

From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

Higher CD4+ T Cell Counts after CAR-T in Large B-Cell Lymphomas Are Significantly Associated with Better Overall Survival

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Patterns and Safety of Glucocorticosteroids Use Following CD19 CAR-T Cell Therapy for B-Cell Lymphoma

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia

Characterization of the Humoral and Cellular Immune Response Against the Natural Infection By Sars-Cov-2 in Oncohematological Patients with Post-COVID19 Autologous Transplantation

Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only